Third-Trimester Maternal Vaccination Against Pertussis and Pertussis Antibody Concentrations.

Publication Date

2018

Journal Title

Obstet Gynecol

Abstract

OBJECTIVE: To compare pertussis antibody concentrations in maternal venous serum (at the time of delivery) and umbilical cord arterial serum among women vaccinated with the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine from either 27-30 6/7 weeks of gestation or from 31-35 6/7 weeks of gestation.

METHODS: We conducted a prospective cohort study of pregnant women divided into two groups based on when Tdap was administered: 27-30 6/7 weeks of gestation and 31-35 6/7 weeks of gestation. Paired maternal and umbilical cord samples were obtained at the time of delivery to determine immunoglobulin G (IgG) concentrations to pertussis toxin and pertactin.

RESULTS: Eighty-eight pregnant women were enrolled. Cord serum pertussis toxin IgG concentrations were approximately twice maternal serum pertussis toxin IgG concentrations (91.6 vs 48.6 enzyme-linked immunoassay [ELISA] units/mL, P

CONCLUSION: Maternal vaccination against pertussis between 27 and 36 weeks of gestation was associated with a high percentage of newborns with antibody concentrations conferring protection and did not vary by gestational age at vaccination.

Volume Number

131

Issue Number

2

Pages

364-369

Document Type

Article

Status

Faculty, Northwell Researcher, Northwell Resident

Facility

School of Medicine; Northwell Health

Primary Department

Obstetrics and Gynecology

PMID

29324612

DOI

10.1097/AOG.0000000000002438

For the public and Northwell Health campuses

Share

COinS